Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCTHO1429

Title

An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Principal Investigator(s)

Leora Horn

Details

  • Protocol No. VICCTHO1429
  • Open Date: 08/05/2014
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: - To assess the safety and tolerability of ASP8273. - To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) based on dose limiting toxicities (DLT) of ASP8273.
  • Disease Sites: Lung
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: ASP8273
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT02113813
  • Secondary Protocol No: 8273-CL-0102

Description

You are being asked to take part in this research study because you have advanced Non-Small Cell Lung Cancer (NSCLC). The purpose of this study is to assess the safety of ASP8273 and to determine a safe dose of the study drug in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The information collected in this study is necessary to find out whether the treatment tested is effective and safe. The information about you will be kept anonymous. Information may be used for seeking approval from the regulatory authorities to market the medicine for NSCLC. It may also be used in reports of the study or for scientific presentations. Astellas may also use the information from this study for future medical research.

Eligibility

Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Criteria

Inclusion Criteria:
• Non-child bearing potential or able to follow birth control requirements
• Eastern Cooperative Oncology Group (ECOG) ≤ 1
• Life expectancy ≥ 12 weeks
• Laboratory criteria as:
• Neutrophil count ≥ 1,500/mm3
• Platelet count ≥ 7.5 x 104 /mm3
• Hemoglobin ≥ 9.0 g/dL
• Lymphocyte count ≥ 500/mm3
• Serum creatinine < 1.5 x institutional Upper Limit of Normal (ULN) or an estimated glomerular filtration rate (eGFR) of > 50 ml/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation
• Total bilirubin < 1.5 x ULN (except for subjects with documented Gilbert's syndrome)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
• Dose escalation subjects: Epidermal Growth Factor Receptor (EGFR) activating mutation by local testing: exon 18 G719X, exon 19 deletion, exon 21 L861Q, exon 21 L858R or exon 20 insertion; and received prior treatment with EGFR Tyrosine Kinase Inhibitor (TKI)
• Response expansion/RP2D expansion subjects: disease progression on or was intolerant to prior EGFR TKI; no anticancer treatment subsequent to EGFR TKI; activating mutation as above AND T790M mutation; tumor sample subsequent to EGFR TKI is available for central testing; at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Exclusion Criteria:
• Any ongoing toxicity ≥ Grade 2 attributable to prior Non-Small-Cell Lung Cancer (NSCLC) treatment
• Prior reversible EGFR inhibitor within 7 days; received prior treatment with any other agent with antitumor activity chemotherapy, radiotherapy, or immunotherapy within 14 days; any investigational therapy within 28 days or 5 half-lives, whichever is shorter; blood transfusion or hemopoietic factor within 14 days; major surgery within 14 days; any strong CYP3A4 inhibitors within 7 days
• Positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) or Human Immunodeficiency Virus (HIV)
• Symptomatic Central Nervous System (CNS) metastasis
• Active infection requiring systemic therapy within 14 days
• Severe or uncontrolled systemic diseases including uncontrolled hypertension
• History of or active interstitial lung disease
• Screening QTcF >450 msec or current medication known to prolong QT
• ≥ Grade 2 cardiac arrhythmia or uncontrolled atrial fib of any grade; Class 3 or 4 New York Heart Association congestive heart failure; history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months
• History of gastrointestinal ulcer or bleeding within 3 months; any digestive tract dysfunction
• Concurrent corneal disorder or ophthalmologic condition making subject unsuitable
• RP2D cohort subjects: contraindications to midazolam, any other midazolam within 7 days, or any medications or supplements known to be strong CYP3A inhibitors within 7 days or inducers within 12 days
• Any other malignancy requiring treatment